The EMPA-REG OUTCOME study published in NEJM showed multipe interesting effects of EMPAGLIFLOZIN, a sodium-glucose cotransporter 2 inhibitor, regarding redaction of cardiovascular morbidity in patients with type-2 diabetes.
The study randomized 7020 patients in 2 different doses of Empagliflozin (10 or 25mg) or placebo with primary composite outcome death from cardiovascular causes, not fatal myocardial infarction, or non fatal stroke.
Results showed statistically significant between group differences in death from cardiovascular causes, hospitalization for heart failure and death from any cause.
The mechanisms are still under investigation, however these effects are possibly attributed to pleiotropic effects of the drug, such as its anti-hypertensive action and weight reduction and of SGLT-2 inhibitor.
For the full study click the link: http://www.nejm.org/doi/pdf/10.1056/NEJMoa1504720
Source: PUBMED, NEJM
No comments:
Post a Comment